

In the Claims:

Please rewrite the claims as follows:

1. (original) Transdermal drug delivery system (TDS) comprising
 - a cover which is impermeable for the active ingredient,
 - a matrix containing oxybutynin as active ingredient and
 - a facultative release liner, wherein the matrix further comprises
 - an Aloe Vera extract,
 - a pressure sensitive adhesive and
 - a cross linking agent for the adhesive.
2. (original) Transdermal drug delivery system according to claim 1, comprising racemic oxybutynin, R-oxybutynin, S-oxybutynin or desethyl-oxybutynin.
3. (currently amended) Transdermal drug delivery according to claim 1 ~~or 2~~, wherein the pressure sensitive adhesive of the matrix ~~comprises or consists~~ is comprised of an acrylate based polymer, preferably a polymer based on an acrylate-vinyl acetate copolymer.
4. (currently amended) Transdermal drug delivery system according to ~~any of the preceding claims~~ claim 1, wherein the matrix ~~comprises or consists~~ is comprised of Durotak 2287 or Durotak 2516.
5. (currently amended) Transdermal drug delivery system according to ~~any of the preceding claims~~ claim 1, wherein the matrix comprises Ti-acetylacetonate, Al-acetylacetonate or polybutyl-titanate as crosslinking agent.
6. (currently amended) Transdermal drug delivery system according to ~~any of the preceding claims~~ claim 1, wherein the extracting agent of the Aloe Vera-extract is a vegetable oil, preferably soybean oil.

7. (original) Transdermal drug delivery system according to claim 6, wherein the Aloe Vera-extract comprises 5 to 15 % by weight of Aloe Vera oil and 95 to 85 % by weight of vegetable oil.
8. (currently amended) Transdermal drug delivery system according to ~~any of the preceding claims~~ claim 1, wherein the matrix comprises the Aloe Vera-extract as the only enhancer.
9. (currently amended) Transdermal drug delivery system according to ~~any of the preceding claims~~ claim 1, wherein the matrix comprises 5 to 40, preferably 10 to 35 and especially 15 to 30 % by weight of oxybutynin (based on the matrix).
10. (currently amended) Transdermal drug delivery system according to ~~any of the preceding claims~~ claim 1, wherein the matrix comprises 10 to 25, preferably 12 to 20 and especially 14 to 18 % by weight of Aloe Vera-extract (based on the matrix).
11. (currently amended) Transdermal drug delivery system according to ~~any of the preceding claims~~ claim 1, wherein the matrix comprises 0.1 to 5.0, preferably 0.3 to 3 and especially 0.5 to 2.0 % by weight of the crosslinking agent (based on the matrix).
12. (currently amended) Transdermal drug delivery system according to ~~any of the preceding claims~~ claim 1, wherein the system has a surface of 5 to 80, preferably 10 to 60 and especially 20 to 50 cm².